Indian drugmaker Cadila Healthcare Ltd said on Monday it would seek local regulatory approval to treat COVID-19 patients with an already approved Hepatitis C drug, following promising interim results from a late-stage trial.
Reuters
April 05, 2021 / 08:44 AM IST
Indian drugmaker Cadila Healthcare Ltd said on Monday it would seek local regulatory approval to treat COVID-19 patients with an already approved Hepatitis C drug, following promising interim results from a late-stage trial.
More details awaited
